| Expression pattern: |
UP |
| Associated gene: |
EZH2 |
| Associated microRNA: |
miR-377, miR-382, miR-498 |
| Biological function: |
Promotes NSCLC cell proliferation, cell cycle progression, tumor growth and tumorigenicity; high expression is associated with larger tumor size, lymph node metastasis, later clinical TNM stage and worse prognosis. |
| Molecular mechanism: |
circ-PRMT5 acts as a cytoplasmic miRNA sponge for miR-377, miR-382 and miR-498, relieving their repression of EZH2 and increasing EZH2 expression to promote NSCLC growth. |
| Biological pathway or process: |
proliferation (promotes); cell cycle (promotes); ceRNA regulation (promotes) |
| Detected method: |
Q
M
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; RT-qPCR; Microarray; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; RNA Pull-Down; Luciferase Reporter Assay; Transfection; CCK8; EdU Staining; Colony Formation Assay; Cell Cycle Assay; In Vivo Animal Model; Western Blot; IHC (Immunohistochemistry); Cohort Study; Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
High circ-PRMT5 expression is positively correlated with larger tumor size, advanced clinical stage, lymph node metastasis, poor overall survival and poor progression-free survival; circ-PRMT5 is an independent prognostic factor and may be a promising prognostic biomarker for NSCLC patients. |
| Description: |
circ-PRMT5 is up-regulated in NSCLC tissues and cell lines and is associated with aggressive clinicopathological features and poor survival. It promotes NSCLC proliferation and xenograft tumor growth by sponging miR-377, miR-382 and miR-498, thereby upregulating EZH2. The study supports circ-PRMT5 as an oncogenic circRNA and potential prognostic biomarker in NSCLC. |
| Confidence score: |
0.8823 |